Sign In
Buy ADPT
$15.99
+0.85 (+5.61%)
At Close: Jun 03, 2026
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation $ADPT Stock Position Reduced by Campbell & CO Investment Adviser LLC
04:38am, Monday, 17'th Nov 2025
Campbell and CO Investment Adviser LLC trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 76.7% in the second quarter, according to its most recent 13F filing with the Secu
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 06'th Nov 2025
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript
07:56am, Thursday, 06'th Nov 2025
Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder,
Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say
08:31pm, Wednesday, 05'th Nov 2025
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
07:36pm, Wednesday, 05'th Nov 2025
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago.
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Wednesday, 29'th Oct 2025
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 15'th Oct 2025
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
10:40am, Friday, 26'th Sep 2025
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
03:58pm, Wednesday, 10'th Sep 2025
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Chad Robins - Co-Founder, CEO & Chairman
Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice
01:01pm, Monday, 01'st Sep 2025
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
04:05pm, Wednesday, 27'th Aug 2025
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 25'th Aug 2025
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
10:15am, Wednesday, 13'th Aug 2025
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
